BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9613790)

  • 1. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
    Heying R; Nürnberger W; Spiekerkötter U; Göbel U
    Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S; Rodriguez M; Lafuente A; Mateos P; Mehta J; Singhal S; Saso R; Tait D; Treleaven JG; Powles RL
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
    Söhngen D; Bauser U; Boogen C; Aul C; Frieling T; Germing U; Schneider P; Kobbe G; Heyll A
    Thromb Haemost; 1997 Oct; 78(4):1299-300. PubMed ID: 9365005
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
    Terra SG; Spitzer TR; Tsunoda SM
    Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.
    Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
    Bone Marrow Transplant; 2000 May; 25(9):993-6. PubMed ID: 10800069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease.
    Palladino M; Miele L; Pompili M; Forgione A; Vellone V; Vecchio FM; Chiusolo P; Laurenti L; Gasbarrini G; Sica S; Grieco A
    Clin Transplant; 2008; 22(6):837-41. PubMed ID: 18713263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
    Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
    Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
    Goldberg SL; Shubert J; Rao AK; Redei I; Klumpp TR; Mangan KF
    Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
    Baglin TP; Harper P; Marcus RE
    Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
    Toh HC; McAfee SL; Sackstein R; Cox BF; Colby C; Spitzer TR
    Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
    Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.